

This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

October 30, 2025

To whom it may concern:

| | |
|----------------|---|
| Company | D.Western Therapeutics Institute, Inc. |
| Representative | Yuichi Hidaka, President and CEO (Securities code: 4576; TSE Growth) |
| Contact | Sayako Matsubara, Director |
| TEL | 052-218-8785 |

Notice Concerning Results of Joint Research with DKS Co. Ltd.

We are conducting joint research with DKS Co. Ltd. (Head office: Kyoto, Kyoto Prefecture; President & CEO: YAMAJI Naoki) to develop a drug for the treatment of dry eye. We are pleased to announce that this joint research has produced positive results, as detailed in the attached document.

This matter will not result in any revisions to the earnings forecast for the fiscal year ending December 2025. However, it will contribute to the expansion of our ophthalmology pipeline over the medium to long term.

End

To our stakeholders:

DKS Co. Ltd.
D. Western Therapeutics Institute, Inc.

Positive Results Obtained in Development of Treatment for Dry Eyes!

~The result of joint research between DKS and D. Western Therapeutics Institute~

DKS Co. Ltd. (Head office: Kyoto, Kyoto Prefecture; President & CEO: YAMAJI Naoki; hereinafter “DKS”) and D. Western Therapeutics Institute, Inc. (Head office: Nagoya, Aichi Prefecture; President and CEO: HIDAKA Yuichi; hereinafter “DWTI”) are pleased to jointly announce that positive results have been achieved in a joint research project (hereinafter “the Joint Research”) aimed at developing a treatment for dry eye.

With the launch of the Joint Research in December 2024, DKS has assumed responsibility for synthesizing the compound using drug discovery technology based on the synthesis technologies it has cultivated to date. Utilizing its proprietary ophthalmology-specific evaluation technologies, DWTI has verified the compound’s potential as a dry eye treatment through efficacy and pharmacological testing. As a result, the pharmacological effects were confirmed in animal dry eye models, and the Joint Research agreement was extended to conduct additional verification.

The technical results and intellectual property rights resulting from the Joint Research will be managed as the joint property of both parties. Through this project, DKS and DWTI will promote evidence-based initiatives aimed at extending healthy lifespans and improving quality of life (QOL).

(About DKS Co. Ltd.)

DKS is a chemical materials manufacturer known as a leader in industrial chemicals. Founded in 1909, the Company began by developing a silkworm cocoon unwinding agent, a chemical for spinning waste cocoons. With the credo “Contributing to the nation and society through industry” and the mottoes “Quality first,” “Cost reduction,” and “R&D efforts”, DKS aims to become a Uni-Top Company recognized for its uniqueness. Its aim is to be a smart chemical partner that uses the power of chemistry to help resolve a variety of social issues.

For more details, please visit the DKS website: <https://www.dks-web.co.jp/english/>

(About D. Western Therapeutics Institute, Inc.)

DWTI is a biotech venture company whose vision is to bring “innovative new drugs to the world from Japan,” with the goal of providing more effective medicines to patients as the earliest opportunity. Possessing strengths in the creation of kinase inhibitors (small molecular weight compounds), DWTI has marketed drugs that have been developed in house.

Currently, DWTI is focusing on the field of ophthalmology, working on regenerative medicine products and other areas to contribute to providing optimal treatment to patients.

For more details, please visit the DWTI website: <https://dwti.co.jp/english/>

Inquiries

| | |
|--|--|
| DKS Co. Ltd. | D. Western Therapeutics Institute, Inc. |
| Public Relations & Investor Relations Department | Corporate Management Department |
| Strategic Management Division | Tel: +81-52-218-8785 |
| Tel: +81-75-276-3027 | E-mail: info@dwti.co.jp |
| E-mail: d-kouhou@dks-web.co.jp | 1-18-11, Nishiki, Naka-ku, Nagoya |
| 48-2, Higashikujo-Kamitonodacho, Minami-ku, Kyoto 601-8002, Japan | Aichi Prefecture 460-0003, Japan |